Understanding how ATRX affects cancer treatment response
Role of ATRX, a chromatin remodeler, in immunotherapy response
This study is looking at how a gene called ATRX affects how well advanced cancer patients respond to immunotherapy treatments, like anti-PD-1, to help find ways to make these treatments work better for more people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Greater Los Angeles Healthcare System NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11109478 on NIH RePORTER |
What this research studies
This research investigates the role of ATRX, a chromatin remodeler, in the response of advanced cancer patients to immunotherapy, specifically anti-PD-1 treatments. The study aims to uncover the mechanisms behind why some patients do not benefit from these therapies, focusing on genetic mutations that may influence treatment outcomes. By examining the effects of ATRX loss on tumor behavior and immune response, researchers hope to identify new strategies to enhance the effectiveness of immunotherapy for more patients. The approach includes both laboratory experiments and in vivo mouse models to validate findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancer who are undergoing or considering anti-PD-1 immunotherapy.
Not a fit: Patients with early-stage cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy strategies that benefit a larger number of patients with advanced cancer.
How similar studies have performed: Other research has shown promising results in understanding the genetic factors influencing immunotherapy response, making this study a continuation of that important work.
Where this research is happening
Los Angeles, United States
- VA Greater Los Angeles Healthcare System — Los Angeles, United States (Active)
Researchers
- Principal investigator: Shin, Daniel Sanghoon — VA Greater Los Angeles Healthcare System
- Study coordinator: Shin, Daniel Sanghoon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.